IBDEI06J ; ; 18-NOV-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;NOV 18, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8505,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8505,1,4,0)
 ;;=4^285.29
 ;;^UTILITY(U,$J,358.3,8505,1,5,0)
 ;;=5^Anemia Of Chronic Dis
 ;;^UTILITY(U,$J,358.3,8505,2)
 ;;=^321979
 ;;^UTILITY(U,$J,358.3,8506,0)
 ;;=284.9^^60^586^13
 ;;^UTILITY(U,$J,358.3,8506,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8506,1,4,0)
 ;;=4^284.9
 ;;^UTILITY(U,$J,358.3,8506,1,5,0)
 ;;=5^Aplastic Anemia Nos
 ;;^UTILITY(U,$J,358.3,8506,2)
 ;;=^7020
 ;;^UTILITY(U,$J,358.3,8507,0)
 ;;=282.61^^60^586^75
 ;;^UTILITY(U,$J,358.3,8507,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8507,1,4,0)
 ;;=4^282.61
 ;;^UTILITY(U,$J,358.3,8507,1,5,0)
 ;;=5^Hemoglobin S Disease
 ;;^UTILITY(U,$J,358.3,8507,2)
 ;;=^267981
 ;;^UTILITY(U,$J,358.3,8508,0)
 ;;=282.7^^60^586^74
 ;;^UTILITY(U,$J,358.3,8508,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8508,1,4,0)
 ;;=4^282.7
 ;;^UTILITY(U,$J,358.3,8508,1,5,0)
 ;;=5^Hemoglobin C Disease
 ;;^UTILITY(U,$J,358.3,8508,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,8509,0)
 ;;=283.9^^60^586^77
 ;;^UTILITY(U,$J,358.3,8509,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8509,1,4,0)
 ;;=4^283.9
 ;;^UTILITY(U,$J,358.3,8509,1,5,0)
 ;;=5^Hemolytic Anemia , Acquired
 ;;^UTILITY(U,$J,358.3,8509,2)
 ;;=^7071
 ;;^UTILITY(U,$J,358.3,8510,0)
 ;;=283.0^^60^586^78
 ;;^UTILITY(U,$J,358.3,8510,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8510,1,4,0)
 ;;=4^283.0
 ;;^UTILITY(U,$J,358.3,8510,1,5,0)
 ;;=5^Hemolytic Anemia, Autoimmune
 ;;^UTILITY(U,$J,358.3,8510,2)
 ;;=^7079
 ;;^UTILITY(U,$J,358.3,8511,0)
 ;;=282.9^^60^586^76
 ;;^UTILITY(U,$J,358.3,8511,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8511,1,4,0)
 ;;=4^282.9
 ;;^UTILITY(U,$J,358.3,8511,1,5,0)
 ;;=5^Hemolytic Anem, Heredit
 ;;^UTILITY(U,$J,358.3,8511,2)
 ;;=^56578
 ;;^UTILITY(U,$J,358.3,8512,0)
 ;;=283.19^^60^586^79
 ;;^UTILITY(U,$J,358.3,8512,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8512,1,4,0)
 ;;=4^283.19
 ;;^UTILITY(U,$J,358.3,8512,1,5,0)
 ;;=5^Hemolytic Anemia, Microang
 ;;^UTILITY(U,$J,358.3,8512,2)
 ;;=^293664
 ;;^UTILITY(U,$J,358.3,8513,0)
 ;;=280.9^^60^586^83
 ;;^UTILITY(U,$J,358.3,8513,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8513,1,4,0)
 ;;=4^280.9
 ;;^UTILITY(U,$J,358.3,8513,1,5,0)
 ;;=5^Iron Defic Anemia(Unspecified)
 ;;^UTILITY(U,$J,358.3,8513,2)
 ;;=^276946
 ;;^UTILITY(U,$J,358.3,8514,0)
 ;;=285.1^^60^586^81
 ;;^UTILITY(U,$J,358.3,8514,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8514,1,4,0)
 ;;=4^285.1
 ;;^UTILITY(U,$J,358.3,8514,1,5,0)
 ;;=5^Iron Defic Anemia d/t Acute Blood Loss
 ;;^UTILITY(U,$J,358.3,8514,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,8515,0)
 ;;=280.0^^60^586^82
 ;;^UTILITY(U,$J,358.3,8515,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8515,1,4,0)
 ;;=4^280.0
 ;;^UTILITY(U,$J,358.3,8515,1,5,0)
 ;;=5^Iron Defic Anemia d/t Chr Blood Loss
 ;;^UTILITY(U,$J,358.3,8515,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,8516,0)
 ;;=281.9^^60^586^101
 ;;^UTILITY(U,$J,358.3,8516,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8516,1,4,0)
 ;;=4^281.9
 ;;^UTILITY(U,$J,358.3,8516,1,5,0)
 ;;=5^Nutritional Anemia
 ;;^UTILITY(U,$J,358.3,8516,2)
 ;;=^123801
 ;;^UTILITY(U,$J,358.3,8517,0)
 ;;=281.0^^60^586^121
 ;;^UTILITY(U,$J,358.3,8517,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8517,1,4,0)
 ;;=4^281.0
 ;;^UTILITY(U,$J,358.3,8517,1,5,0)
 ;;=5^Vit B12 Deficiency (Pernicious Anemia)
 ;;^UTILITY(U,$J,358.3,8517,2)
 ;;=^7161
 ;;^UTILITY(U,$J,358.3,8518,0)
 ;;=282.60^^60^586^108
 ;;^UTILITY(U,$J,358.3,8518,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8518,1,4,0)
 ;;=4^282.60
 ;;^UTILITY(U,$J,358.3,8518,1,5,0)
 ;;=5^Sickle-Cell Anemia
 ;;^UTILITY(U,$J,358.3,8518,2)
 ;;=^7188
 ;;^UTILITY(U,$J,358.3,8519,0)
 ;;=282.62^^60^586^109
 ;;^UTILITY(U,$J,358.3,8519,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8519,1,4,0)
 ;;=4^282.62
 ;;^UTILITY(U,$J,358.3,8519,1,5,0)
 ;;=5^Sickle-Cell With Crisis
 ;;^UTILITY(U,$J,358.3,8519,2)
 ;;=^267982
 ;;^UTILITY(U,$J,358.3,8520,0)
 ;;=281.1^^60^586^122
 ;;^UTILITY(U,$J,358.3,8520,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8520,1,4,0)
 ;;=4^281.1
 ;;^UTILITY(U,$J,358.3,8520,1,5,0)
 ;;=5^Vit B12 Deficiency(Dietary)
 ;;^UTILITY(U,$J,358.3,8520,2)
 ;;=^267974
 ;;^UTILITY(U,$J,358.3,8521,0)
 ;;=286.7^^60^586^51
 ;;^UTILITY(U,$J,358.3,8521,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8521,1,4,0)
 ;;=4^286.7
 ;;^UTILITY(U,$J,358.3,8521,1,5,0)
 ;;=5^Coagulation Defect(Any),Acquired
 ;;^UTILITY(U,$J,358.3,8521,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,8522,0)
 ;;=289.9^^60^586^118
 ;;^UTILITY(U,$J,358.3,8522,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8522,1,4,0)
 ;;=4^289.9
 ;;^UTILITY(U,$J,358.3,8522,1,5,0)
 ;;=5^Thrombocytosis, Essential
 ;;^UTILITY(U,$J,358.3,8522,2)
 ;;=^55344
 ;;^UTILITY(U,$J,358.3,8523,0)
 ;;=451.9^^60^586^119
 ;;^UTILITY(U,$J,358.3,8523,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8523,1,4,0)
 ;;=4^451.9
 ;;^UTILITY(U,$J,358.3,8523,1,5,0)
 ;;=5^Thrombophlebitis 
 ;;^UTILITY(U,$J,358.3,8523,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,8524,0)
 ;;=446.6^^60^586^120
 ;;^UTILITY(U,$J,358.3,8524,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8524,1,4,0)
 ;;=4^446.6
 ;;^UTILITY(U,$J,358.3,8524,1,5,0)
 ;;=5^Thrombotic Thrombocytopenic Purpura(TTP)
 ;;^UTILITY(U,$J,358.3,8524,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,8525,0)
 ;;=286.4^^60^586^123
 ;;^UTILITY(U,$J,358.3,8525,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8525,1,4,0)
 ;;=4^286.4
 ;;^UTILITY(U,$J,358.3,8525,1,5,0)
 ;;=5^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,8525,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,8526,0)
 ;;=204.00^^60^586^2
 ;;^UTILITY(U,$J,358.3,8526,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8526,1,4,0)
 ;;=4^204.00
 ;;^UTILITY(U,$J,358.3,8526,1,5,0)
 ;;=5^ALL w/o Remission
 ;;^UTILITY(U,$J,358.3,8526,2)
 ;;=^267521
 ;;^UTILITY(U,$J,358.3,8527,0)
 ;;=204.01^^60^586^1
 ;;^UTILITY(U,$J,358.3,8527,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8527,1,4,0)
 ;;=4^204.01
 ;;^UTILITY(U,$J,358.3,8527,1,5,0)
 ;;=5^ALL in Remission
 ;;^UTILITY(U,$J,358.3,8527,2)
 ;;=^267522
 ;;^UTILITY(U,$J,358.3,8528,0)
 ;;=204.10^^60^586^26
 ;;^UTILITY(U,$J,358.3,8528,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8528,1,4,0)
 ;;=4^204.10
 ;;^UTILITY(U,$J,358.3,8528,1,5,0)
 ;;=5^CLL w/o Remission
 ;;^UTILITY(U,$J,358.3,8528,2)
 ;;=^267523
 ;;^UTILITY(U,$J,358.3,8529,0)
 ;;=204.11^^60^586^24
 ;;^UTILITY(U,$J,358.3,8529,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8529,1,4,0)
 ;;=4^204.11
 ;;^UTILITY(U,$J,358.3,8529,1,5,0)
 ;;=5^CLL in Remission
 ;;^UTILITY(U,$J,358.3,8529,2)
 ;;=^267524
 ;;^UTILITY(U,$J,358.3,8530,0)
 ;;=202.41^^60^586^73
 ;;^UTILITY(U,$J,358.3,8530,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8530,1,4,0)
 ;;=4^202.41
 ;;^UTILITY(U,$J,358.3,8530,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspec Site
 ;;^UTILITY(U,$J,358.3,8530,2)
 ;;=^267472
 ;;^UTILITY(U,$J,358.3,8531,0)
 ;;=201.90^^60^586^80
 ;;^UTILITY(U,$J,358.3,8531,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8531,1,4,0)
 ;;=4^201.90
 ;;^UTILITY(U,$J,358.3,8531,1,5,0)
 ;;=5^Hodgkin's Lymphoma,Unspec Type & Site
 ;;^UTILITY(U,$J,358.3,8531,2)
 ;;=^267430
 ;;^UTILITY(U,$J,358.3,8532,0)
 ;;=785.6^^60^586^86
 ;;^UTILITY(U,$J,358.3,8532,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8532,1,4,0)
 ;;=4^785.6
 ;;^UTILITY(U,$J,358.3,8532,1,5,0)
 ;;=5^Lymphadenopathy
 ;;^UTILITY(U,$J,358.3,8532,2)
 ;;=^72368
 ;;^UTILITY(U,$J,358.3,8533,0)
 ;;=200.20^^60^586^89
 ;;^UTILITY(U,$J,358.3,8533,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8533,1,4,0)
 ;;=4^200.20
 ;;^UTILITY(U,$J,358.3,8533,1,5,0)
 ;;=5^Lymphoma,Burkett's,Unspecified Sites
 ;;^UTILITY(U,$J,358.3,8533,2)
 ;;=^17529
 ;;^UTILITY(U,$J,358.3,8534,0)
 ;;=202.00^^60^586^88
 ;;^UTILITY(U,$J,358.3,8534,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8534,1,4,0)
 ;;=4^202.00
 ;;^UTILITY(U,$J,358.3,8534,1,5,0)
 ;;=5^Lymphoma, Low-Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,8534,2)
 ;;=^72606
 ;;^UTILITY(U,$J,358.3,8535,0)
 ;;=200.10^^60^586^87
 ;;^UTILITY(U,$J,358.3,8535,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8535,1,4,0)
 ;;=4^200.10
 ;;^UTILITY(U,$J,358.3,8535,1,5,0)
 ;;=5^Lymphoma, Int Or High Grade, Unspec Site
 ;;^UTILITY(U,$J,358.3,8535,2)
 ;;=^175886
 ;;^UTILITY(U,$J,358.3,8536,0)
 ;;=273.3^^60^586^90
 ;;^UTILITY(U,$J,358.3,8536,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8536,1,4,0)
 ;;=4^273.3
 ;;^UTILITY(U,$J,358.3,8536,1,5,0)
 ;;=5^Macroglobulinemia
 ;;^UTILITY(U,$J,358.3,8536,2)
 ;;=^73013
 ;;^UTILITY(U,$J,358.3,8537,0)
 ;;=203.00^^60^586^99
 ;;^UTILITY(U,$J,358.3,8537,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8537,1,4,0)
 ;;=4^203.00
 ;;^UTILITY(U,$J,358.3,8537,1,5,0)
 ;;=5^Multiple Myeloma W/O Rem
 ;;^UTILITY(U,$J,358.3,8537,2)
 ;;=^267514
 ;;^UTILITY(U,$J,358.3,8538,0)
 ;;=203.01^^60^586^98
 ;;^UTILITY(U,$J,358.3,8538,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8538,1,4,0)
 ;;=4^203.01
 ;;^UTILITY(U,$J,358.3,8538,1,5,0)
 ;;=5^Multiple Myeloma In Remission
 ;;^UTILITY(U,$J,358.3,8538,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,8539,0)
 ;;=238.6^^60^586^102
 ;;^UTILITY(U,$J,358.3,8539,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8539,1,4,0)
 ;;=4^238.6
 ;;^UTILITY(U,$J,358.3,8539,1,5,0)
 ;;=5^Plasmacytoma Nos
 ;;^UTILITY(U,$J,358.3,8539,2)
 ;;=^81973
 ;;^UTILITY(U,$J,358.3,8540,0)
 ;;=205.00^^60^586^5
 ;;^UTILITY(U,$J,358.3,8540,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8540,1,4,0)
 ;;=4^205.00
 ;;^UTILITY(U,$J,358.3,8540,1,5,0)
 ;;=5^AML w/o Remission
 ;;^UTILITY(U,$J,358.3,8540,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,8541,0)
 ;;=205.01^^60^586^4
 ;;^UTILITY(U,$J,358.3,8541,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8541,1,4,0)
 ;;=4^205.01
 ;;^UTILITY(U,$J,358.3,8541,1,5,0)
 ;;=5^AML in Remission
 ;;^UTILITY(U,$J,358.3,8541,2)
 ;;=^267532
 ;;^UTILITY(U,$J,358.3,8542,0)
 ;;=205.10^^60^586^29
 ;;^UTILITY(U,$J,358.3,8542,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,8542,1,4,0)
 ;;=4^205.10
 ;;^UTILITY(U,$J,358.3,8542,1,5,0)
 ;;=5^CML w/o Remission
 ;;^UTILITY(U,$J,358.3,8542,2)
 ;;=^267533
